Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.57 |
| ▸ | GSK3B | P49841 | 11/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 2/20 | 0.46 |
| ▸ | CLK3 | P49761 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16913981 | 0.86 | PIK3C3 (0.62) | MAPTGSK3BMAPK8MAPK10PIK3C3 | |
| SCHEMBL485750 | 0.77 | MAPT (0.50) | MAPTGSK3BNAMPTBCAT2 | |
| SCHEMBL485904 | 0.75 | RAB9A (0.58) | MAPTGSK3BNAMPTCLK2CLK3 | |
| SCHEMBL27982254 | 0.74 | BCAT2 (0.55) | MAPTGSK3BNAMPTDYRK1ABCAT2 | |
| SCHEMBL19065434 | 0.73 | CLK2 (0.52) | MAPTGSK3BCLK2CLK3DYRK1A | |
| SCHEMBL29675461 | 0.73 | CLK2 (0.52) | MAPTGSK3BCLK2CLK3DYRK1A | |
| SCHEMBL730182 | 0.73 | PIK3CA (0.59) | MAPTGSK3BCLK2CLK3DYRK1A | |
| SCHEMBL16703333 | 0.72 | GSK3B (1.00) | MAPTGSK3B | |
| SCHEMBL28655226 | 0.72 | NPC1 (0.65) | MAPK8MAPK10FDPS | |
| SCHEMBL18086917 | 0.72 | GSK3B (0.70) | MAPTGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10538533-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-01-21 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | MAPT 3994/4885GSK3B 2235/4885MAPK8 4049/4885 |
| US-10538533-B2 | Heteroaryls and uses thereof | VPS35, VPS4B, VPS26B | MAPT 3994/4885GSK3B 2235/4885MAPK8 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.